Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Vermunt, Lisa ; Wallin, Åsa LU and Visser, Pieter-Jelle (2019) In Alzheimer's and Dementia 15(7). p.888-898
Abstract
Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal... (More)
Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design. © 2019 the Alzheimer's Association (Less)
Please use this url to cite or link to this publication:
author
; and
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, APOE, Clinical setting, Dementia, Disease duration, Multistate model, Preclinical, Prodromal, Progression
in
Alzheimer's and Dementia
volume
15
issue
7
pages
888 - 898
publisher
Wiley
external identifiers
  • scopus:85066298869
  • pmid:31164314
ISSN
1552-5279
DOI
10.1016/j.jalz.2019.04.001
language
English
LU publication?
yes
additional info
Export Date: 18 June 2019
id
3fdc90f7-a70c-4947-aa85-0c03da727c04
date added to LUP
2019-06-18 08:10:52
date last changed
2022-05-11 18:35:58
@article{3fdc90f7-a70c-4947-aa85-0c03da727c04,
  abstract     = {{Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design. © 2019 the Alzheimer's Association}},
  author       = {{Vermunt, Lisa and Wallin, Åsa and Visser, Pieter-Jelle}},
  issn         = {{1552-5279}},
  keywords     = {{Alzheimer's disease; APOE; Clinical setting; Dementia; Disease duration; Multistate model; Preclinical; Prodromal; Progression}},
  language     = {{eng}},
  month        = {{06}},
  number       = {{7}},
  pages        = {{888--898}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype}},
  url          = {{http://dx.doi.org/10.1016/j.jalz.2019.04.001}},
  doi          = {{10.1016/j.jalz.2019.04.001}},
  volume       = {{15}},
  year         = {{2019}},
}